CEBPA and acute myeloid leukemia: The overexpression of Trib2 in AML does not result in total C/EBPα degradation in the tumor cells; instead, there appears to be preferential degradation of the p42 C/EBPα isoform that results in a relative increase in expression of the p30 C/EBPα isoform [6].